<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003213</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 90/95</org_study_id>
    <secondary_id>SWS-SAKK-90/95</secondary_id>
    <secondary_id>EU-97035</secondary_id>
    <secondary_id>CDR0000066073</secondary_id>
    <nct_id>NCT00003213</nct_id>
  </id_info>
  <brief_title>Drugs to Reduce the Side Effects of Chemotherapy</brief_title>
  <official_title>A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients
      treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron
      is more effective than receiving dexamethasone with metoclopramide for reducing the side
      effects of chemotherapy.

      PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either
      granisetron or metoclopramide in patients treated with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the clinical efficacy and safety of Granisetron or Metoclopramide in
      combination with Dexamethasone in the prophylaxis of delayed nausea and vomiting induced by
      emetogenic cancer chemotherapy in patients with or without emesis in the acute phase.

      OUTLINE: This is a randomized, double blind study. Patients are stratified by prior
      chemotherapy (yes vs no), regular alcohol consumption (yes vs no), and prior chemotherapy
      regimen (cisplatin/carboplatin vs others). Patients receive dexamethasone and granisetron by
      mouth bid on day 0. Patients are then randomized to receive either granisetron or
      metoclopramide with dexamethasone concurrently with chemotherapy. Arm I: Patients receive
      granisetron by mouth bid on days 1-5. Dexamethasone and a placebo are administered by mouth
      once daily on days 1-5. Arm II: Patients receive metoclopramide by mouth tid on days 1-5.
      Dexamethasone is administered by mouth once daily on days 1-5. Patients must complete a diary
      card daily for 6 days.

      PROJECTED ACCRUAL: This study will accrue 360 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date type="Actual">August 1999</completion_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete and partial control of emesis</measure>
    <time_frame>Total control of emesis on every one of the 5 days following the acute phase</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Nausea and Vomiting</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Oral Granisetron + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg Granisetron in the morning
1 Metoclopramide placebo in the afternoon
1 mg Granisetron in the evening 4 mg Dexamethasone in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>4 mg Dexamethasone in the morning</description>
    <arm_group_label>Oral Granisetron + Dexamethasone</arm_group_label>
    <arm_group_label>Metoclopramide + Dexamethasone</arm_group_label>
    <other_name>dexamethasone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granisetron hydrochloride</intervention_name>
    <description>1 mg Granisetron in the morning</description>
    <arm_group_label>Oral Granisetron + Dexamethasone</arm_group_label>
    <other_name>Kytril®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide hydrochloride</intervention_name>
    <description>20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)</description>
    <arm_group_label>Metoclopramide + Dexamethasone</arm_group_label>
    <other_name>Metozolv®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Scheduled to receive a first course of highly emetogenic single
        day cancer chemotherapy regimens including: Cisplatin at least 50 mg/m2 Carboplatin at
        least 300 mg/m2 Dacarbazine at least 500 mg/m2 Doxorubicin at least 40 mg/m2 Epirubicin at
        least 60 mg/m2 Ifosfamide at least 1200 mg/m2 Cyclophosphamide at least 600 mg/m2

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: Must be able to complete diary card (fluent in German, French, or Italian)
        No severe concurrent illness No other etiologies that cause vomiting, including:
        Gastrointestinal obstruction Hypercalcemia CNS metastases No active peptic ulceration No
        prior gastrointestinal bleeding due to peptic ulcer No moderate to severe nausea or any
        vomiting in the 24 hours prior to chemotherapy Not pregnant or lactating

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months
        since prior chemotherapy Concurrent etoposide and fluorouracil allowed (days 1-5) No
        chemotherapy before day 0 of study Endocrine therapy: Not specified Radiotherapy: Not
        specified Surgery: Not specified Other: No other concurrent antiemetics No concurrent high
        dose benzodiazepines No concurrent psychotropic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti S. Aapro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Walter Weber-Stadelman</name>
      <address>
        <city>Basel</city>
        <zip>CH 4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burgerspital, Solothurn</name>
      <address>
        <city>Solothurn</city>
        <zip>4500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol. 2003 Feb;14(2):291-7.</citation>
    <PMID>12562658</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS; Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002 Jan 1;20(1):65-72.</citation>
    <PMID>11773155</PMID>
  </results_reference>
  <results_reference>
    <citation>Aapro MS, Sessa C, Thurlimann B, et al.: SAKK 90/95: a randomized double-blind trial to compare the clinical efficacy of granisetron to metoclopramide, both combined to dexamethasone in the prophylaxis of chemotherapy induced delayed emesis. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2360, 2000.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2004</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

